

Gautam Borthakur

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1283025/publications.pdf>

Version: 2024-02-01

203
papers

12,002
citations

22153

59
h-index

32842

100
g-index

203
all docs

203
docs citations

203
times ranked

10080
citing authors

#	ARTICLE	IF	CITATIONS
1	Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline "chemotherapy-free"™ therapy. <i>Leukemia and Lymphoma</i> , 2022, 63, 672-675.	1.3	2
2	Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2. <i>Blood</i> , 2022, 139, 907-921.	1.4	34
3	Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy. <i>American Journal of Hematology</i> , 2022, 97, 68-78.	4.1	25
4	Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. <i>Blood Cancer Journal</i> , 2022, 12, 10.	6.2	48
5	Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure. <i>Journal of Hematology and Oncology</i> , 2022, 15, 12.	17.0	13
6	Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells. <i>Blood Cancer Journal</i> , 2022, 12, 23.	6.2	4
7	Improved outcomes among newly diagnosed patients with <scp>FMS-like tyrosine kinase 3 internal tandem duplication</scp> mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification. <i>American Journal of Hematology</i> , 2022, 97, 329-337.	4.1	15
8	Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, 574-582.	4.1	9
9	Targeting the NOTCH1-MYC-CD44 axis in leukemia-initiating cells in T-ALL. <i>Leukemia</i> , 2022, 36, 1261-1273.	7.2	12
10	3q2CBFB deletion in CFBF-rearranged acute myeloid leukemia retains morphological features associated with inv(16), but patients have higher risk of relapse and may require stem cell transplant. <i>Annals of Hematology</i> , 2022, 101, 847-854.	1.8	2
11	<scp>Treatment-free</scp> remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , 2022, 97, 856-864.	4.1	33
12	Prediction of survival with intensive chemotherapy in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, 865-876.	4.1	12
13	Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2022, 63, 463-467.	1.3	13
14	Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. <i>American Journal of Hematology</i> , 2022, 97, 885-894.	4.1	4
15	A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2022, 63, 2161-2170.	1.3	12
16	Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. <i>Lancet Haematology</i> , 2022, 9, e350-e360.	4.6	26
17	Hypomethylating agent and venetoclax with FLT3 inhibitor "co-triplet" therapy in older/unfit patients with FLT3 mutated AML. <i>Blood Cancer Journal</i> , 2022, 12, 77.	6.2	33
18	Venetoclax combined with <scp>FLAG-IDA</scp> induction and consolidation in newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, 1035-1043.	4.1	31

#	ARTICLE	IF	CITATIONS
19	Major Clinical Response in a Patient with Leukemia Cutis Treated with the Bromodomain Inhibitor PLX51107 and Azacitidine. <i>Leukemia Research</i> , 2022, 119, 106884.	0.8	1
20	Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 3848-3857.	1.6	41
21	The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia. <i>Leukemia</i> , 2021, 35, 691-700.	7.2	37
22	Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. <i>American Journal of Hematology</i> , 2021, 96, E50-E53.	4.1	8
23	Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. <i>American Journal of Hematology</i> , 2021, 96, 282-291.	4.1	59
24	Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 Inhibitors. <i>Blood Cancer Discovery</i> , 2021, 2, 125-134.	5.0	50
25	The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes. <i>American Journal of Hematology</i> , 2021, 96, 241-250.	4.1	19
26	Bromodomain and extra-terminal (BET) inhibitors in treating myeloid neoplasms. <i>Leukemia and Lymphoma</i> , 2021, 62, 528-537.	1.3	15
27	Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience. <i>Leukemia and Lymphoma</i> , 2021, 62, 909-917.	1.3	11
28	Phase 1 study to evaluate Crenigacestat (LY3039478) in combination with dexamethasone in patients with T-cell acute lymphoblastic leukemia and lymphoma. <i>Cancer</i> , 2021, 127, 372-380.	4.1	25
29	Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure. <i>International Journal of Laboratory Hematology</i> , 2021, 43, e19-e25.	1.3	6
30	Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2021, 11, 25.	6.2	85
31	Acute myeloid leukemia: current progress and future directions. <i>Blood Cancer Journal</i> , 2021, 11, 41.	6.2	313
32	Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study. <i>Blood Cancer Journal</i> , 2021, 11, 60.	6.2	22
33	Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. <i>Blood Cancer Journal</i> , 2021, 11, 52.	6.2	5
34	Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs. <i>Blood Advances</i> , 2021, 5, 2156-2164.	5.2	33
35	A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. <i>Haematologica</i> , 2021, 106, 2121-2130.	3.5	34
36	Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 1876-1883.	5.2	56

#	ARTICLE	IF	CITATIONS
37	Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. <i>Leukemia</i> , 2021, 35, 1494-1499.	7.2	16
38	De novo acute myeloid leukemia: A population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. <i>Cancer</i> , 2021, 127, 2049-2061.	4.1	79
39	Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. <i>Blood Cancer Journal</i> , 2021, 11, 98.	6.2	24
40	Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). <i>Blood Advances</i> , 2021, 5, 2481-2489.	5.2	25
41	Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. <i>Leukemia</i> , 2021, 35, 3421-3429.	7.2	22
42	Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, 914-924.	4.1	13
43	A phase 1b/2 study of azacitidine with PD-1 antibody avelumab in relapsed/refractory acute myeloid leukemia. <i>Cancer</i> , 2021, 127, 3761-3771.	4.1	34
44	Core binding factor acute myelogenous leukemia-2021 treatment algorithm. <i>Blood Cancer Journal</i> , 2021, 11, 114.	6.2	49
45	Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2021, 8, e552-e561.	4.6	81
46	Phase II study of azacitidine with pembrolizumab in patients with intermediate or higher risk myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2021, 195, 378-387.	2.5	32
47	Clinical and molecular characterization of myeloid sarcoma without medullary leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 3402-3410.	1.3	12
48	Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis. <i>Cancer</i> , 2021, 127, 4213-4220.	4.1	24
49	Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. <i>Blood Cancer Journal</i> , 2021, 11, 162.	6.2	32
50	Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2021, 39, 2768-2778.	1.6	173
51	CBFB Break-Apart FISH Testing: An Analysis of 1629 AML Cases with a Focus on Atypical Findings and Their Implications in Clinical Diagnosis and Management. <i>Cancers</i> , 2021, 13, 5354.	3.7	3
52	Acute myeloid leukemia with a novel CPSF6-RARG variant is sensitive to homoharringtonine and cytarabine chemotherapy. <i>American Journal of Hematology</i> , 2020, 95, E48-E51.	4.1	19
53	Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. <i>Journal of Hematology and Oncology</i> , 2020, 13, 132.	17.0	18
54	10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. <i>Lancet Haematology</i> , 2020, 7, e724-e736.	4.6	201

#	ARTICLE	IF	CITATIONS
55	Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2020, 95, 1288-1295.	4.1	28
56	Apoptosis targeted therapies in acute myeloid leukemia: an update. <i>Expert Review of Hematology</i> , 2020, 13, 1373-1386.	2.2	12
57	Pan-RAF Inhibition Shows Anti-Leukemic Activity in RAS-Mutant Acute Myeloid Leukemia Cells and Potentiates the Effect of Sorafenib in Cells with FLT3 Mutation. <i>Cancers</i> , 2020, 12, 3511.	3.7	13
58	Phase 1 study of combinatorial sorafenib, <i>G-CSF</i> , and plerixafor treatment in relapsed/refractory, <i>FLT3-ITD</i> -mutated acute myelogenous leukemia patients. <i>American Journal of Hematology</i> , 2020, 95, 1296-1303.	4.1	22
59	Survivorship in AML – a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. <i>Leukemia and Lymphoma</i> , 2020, 61, 3120-3127.	1.3	12
60	Natural history of newly diagnosed myelodysplastic syndrome with isolated <i>inv(3)/t(3;3)</i> . <i>American Journal of Hematology</i> , 2020, 95, E326-E329.	4.1	2
61	Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline <i>RUNX1</i> mutations. <i>American Journal of Hematology</i> , 2020, 95, E313-E315.	4.1	4
62	Impact of <i>CD33</i> and <i>ABCB1</i> single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin. <i>American Journal of Hematology</i> , 2020, 95, E225-E228.	4.1	9
63	Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2020, 10, 48.	6.2	22
64	Oral arsenic trioxide ORH-2014 pharmacokinetic and safety profile in patients with advanced hematologic disorders. <i>Haematologica</i> , 2020, 105, 1567-1574.	3.5	25
65	The clinical impact of time to response in de novo accelerated-phase chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2020, 95, 1127-1134.	4.1	8
66	Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. <i>American Journal of Hematology</i> , 2020, 95, 612-622.	4.1	51
67	Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges. <i>Cancer Discovery</i> , 2020, 10, 506-525.	9.4	212
68	Clinical value of event-free survival in acute myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 1690-1699.	5.2	4
69	Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study. <i>American Journal of Hematology</i> , 2020, 95, 799-808.	4.1	26
70	Mechanistic basis and efficacy of targeting the β -catenin/TCF7L2/JMJD6/c-Myc axis to overcome resistance to BET inhibitors. <i>Blood</i> , 2020, 135, 1255-1269.	1.4	27
71	Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. <i>Blood Advances</i> , 2020, 4, 1311-1320.	5.2	106
72	Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML. <i>Blood</i> , 2020, 136, 18-20.	1.4	17

#	ARTICLE	IF	CITATIONS
73	Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results. <i>Blood</i> , 2020, 136, 42-43.	1.4	11
74	Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies.. <i>Journal of Clinical Oncology</i> , 2020, 38, 7500-7500.	1.6	46
75	Venetoclax (Ven) added to intensive chemo with cladribine, idarubicin, and AraC (CLIA) achieves high rates of durable complete remission with low rates of measurable residual disease (MRD) in pts with newly diagnosed acute myeloid leukemia (AML).. <i>Journal of Clinical Oncology</i> , 2020, 38, 7539-7539.	1.6	6
76	MYC protein expression is an important prognostic factor in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 37-48.	1.3	54
77	Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy. <i>Leukemia and Lymphoma</i> , 2019, 60, 3172-3180.	1.3	2
78	Novel treatments for relapsed/refractory acute myeloid leukemia with FLT3 mutations. <i>Expert Review of Hematology</i> , 2019, 12, 621-640.	2.2	1
79	Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia. <i>Cancer</i> , 2019, 125, 3219-3224.	4.1	14
80	Ibrutinib and Venetoclax for First-Line Treatment of CLL. <i>New England Journal of Medicine</i> , 2019, 380, 2095-2103.	27.0	388
81	Topoisomerase II inhibitors in AML: past, present, and future. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1637-1644.	1.8	25
82	Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. <i>American Journal of Hematology</i> , 2019, 94, 984-991.	4.1	32
83	Patient with mixed-phenotype acute leukemia with CFBF rearrangement. <i>Leukemia and Lymphoma</i> , 2019, 60, 2829-2831.	1.3	0
84	Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality. <i>Cancer Cell</i> , 2019, 35, 721-737.e9.	16.8	206
85	Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. <i>International Journal of Hematology</i> , 2019, 109, 545-552.	1.6	25
86	NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated acute myeloid leukemia. <i>American Journal of Hematology</i> , 2019, 94, E158-E160.	4.1	17
87	Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts. <i>American Journal of Hematology</i> , 2019, 94, E188-E190.	4.1	4
88	Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 431-440.e13.	0.4	46
89	A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure. <i>Leukemia and Lymphoma</i> , 2019, 60, 2207-2213.	1.3	11
90	Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. <i>Blood Advances</i> , 2019, 3, 851-861.	5.2	88

#	ARTICLE	IF	CITATIONS
91	Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 142-148.e1.	0.4	39
92	Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. <i>Lancet Haematology</i> , 2019, 6, e29-e37.	4.6	84
93	Targeting nuclear β -catenin as therapy for post-myeloproliferative neoplasm secondary AML. <i>Leukemia</i> , 2019, 33, 1373-1386.	7.2	32
94	Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. <i>Blood Cancer Journal</i> , 2019, 9, 4.	6.2	57
95	Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. <i>Nature Communications</i> , 2019, 10, 244.	12.8	111
96	Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. <i>Journal of Hematology and Oncology</i> , 2019, 12, 1.	17.0	257
97	Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?. <i>Blood Cancer Journal</i> , 2019, 9, 7.	6.2	64
98	BETP degradation simultaneously targets acute myelogenous leukemic stem cells and the microenvironment. <i>Journal of Clinical Investigation</i> , 2019, 129, 1878-1894.	8.2	51
99	Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. <i>Cancer</i> , 2018, 124, 2758-2765.	4.1	78
100	Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 2238-2241.	1.3	20
101	Checkpoint inhibitors and acute myelogenous leukemia: promises and challenges. <i>Expert Review of Hematology</i> , 2018, 11, 373-389.	2.2	25
102	A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 813-820.	1.3	16
103	Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. <i>Leukemia and Lymphoma</i> , 2018, 59, 1312-1322.	1.3	11
104	Outcomes of Patients With Relapsed Core Binding Factor-Positive Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e19-e25.	0.4	14
105	Time to response and survival in hypomethylating agent-treated acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 1012-1015.	1.3	3
106	Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2018, 8, 369.	2.8	25
107	Prognostic significance of hyperdiploidy in adult acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018, 93, E357-E360.	4.1	2
108	Prognosis of patients with intermediate risk IPSS myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS. <i>American Journal of Hematology</i> , 2018, 93, 1245-1253.	4.1	34

#	ARTICLE	IF	CITATIONS
109	Prognosis interfered with by clonal interference. <i>Blood</i> , 2018, 132, 118-119.	1.4	0
110	Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia. <i>American Journal of Hematology</i> , 2018, 93, 1136-1141.	4.1	95
111	Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (iCBF-TJETO). <i>Journal of Clinical Oncology</i> , 2018, 36, 1743-1751.	2.8	17
112	Investigational CHK1 inhibitors in early stage clinical trials for acute myeloid leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 661-666.	4.1	5
113	Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. <i>Lancet Haematology</i> , 2018, 5, e411-e421.	4.6	66
114	Response kinetics and factors predicting survival in core-binding factor leukemia. <i>Leukemia</i> , 2018, 32, 2698-2701.	7.2	20
115	Phase I-II Study of Crenolanib Combined with Standard Salvage Chemotherapy and Crenolanib Combined with 5-Azacytidine in Acute Myeloid Leukemia Patients with FLT3 Activating Mutations. <i>Blood</i> , 2018, 132, 2715-2715.	1.4	9
116	Outcomes with Subsequent FLT3-Inhibitor (FLT3i) Based Therapies in FLT3-Mutated (mu) Patients (pts) Refractory/Relapsed (R/R) to One or More Prior FLT3 Inhibitor Based Therapies: A Single Center Experience. <i>Blood</i> , 2018, 132, 663-663.	1.4	7
117	Final Results of Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML). <i>Blood</i> , 2018, 132, 1441-1441.	1.4	5
118	A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2018, 132, 465-465.	1.4	48
119	Disruption of NOTCH1-MYC-CD44 Axis Targets Leukemia Initiating Cells (LIC) in T-ALL. <i>Blood</i> , 2018, 132, 890-890.	1.4	0
120	Frontline treatment of acute myeloid leukemia in adults. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 110, 20-34.	4.4	105
121	Therapeutic targeting of isocitrate dehydrogenase mutant AML. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 525-530.	4.1	19
122	Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia. <i>American Journal of Hematology</i> , 2017, 92, 845-850.	4.1	36
123	Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. <i>American Journal of Hematology</i> , 2017, 92, 599-606.	4.1	38
124	Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. <i>Blood</i> , 2017, 129, 1275-1283.	1.4	214
125	Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. <i>Haematologica</i> , 2017, 102, 1709-1717.	3.5	13
126	A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. <i>Cancer</i> , 2017, 123, 4430-4439.	4.1	37

#	ARTICLE	IF	CITATIONS
127	Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. <i>Cancer</i> , 2017, 123, 4391-4402.	4.1	114
128	Targeting autophagy to overcome chemoresistance in acute myelogenous leukemia. <i>Autophagy</i> , 2017, 13, 214-215.	9.1	76
129	Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship. <i>Cancer</i> , 2017, 123, 609-616.	4.1	4
130	Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. <i>Cancer</i> , 2017, 123, 426-435.	4.1	63
131	Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. <i>Blood Advances</i> , 2017, 1, 1312-1323.	5.2	83
132	Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1618.	4.1	37
133	The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial. <i>Blood</i> , 2017, 130, 723-723.	1.4	35
134	Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3 -ITD Allelic Ratio in FLT3 -ITD Positive Acute Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1218-1226.	2.0	66
135	Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemia. <i>Blood</i> , 2016, 128, 1260-1269.	1.4	104
136	Final Phase IIa Study Results Evaluating the CXCR4 Antagonist BL-8040 in Combination with Cytarabine (Ara-C) for the Treatment of Relapsed/Refractory AML Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S28.	0.4	1
137	Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 616-624.	0.4	11
138	<i>TP53</i> mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. <i>Cancer</i> , 2016, 122, 3484-3491.	4.1	200
139	Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia. <i>American Journal of Clinical Pathology</i> , 2016, 145, 769-777.	0.7	39
140	Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in <i>RAS</i> mutant relapsed or refractory myeloid malignancies. <i>Cancer</i> , 2016, 122, 1871-1879.	4.1	113
141	Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 163-168.e2.	0.4	18
142	Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 213-222.e2.	0.4	26
143	ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. <i>Science Signaling</i> , 2016, 9, ra17.	3.6	147
144	The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Confering FLT3 Mutations. <i>Cancer Research</i> , 2016, 76, 1528-1537.	0.9	45

#	ARTICLE	IF	CITATIONS
145	Efficacy of a Type I FLT3 Inhibitor, Crenolanib, with Idarubicin and High-Dose Ara-C in Multiply Relapsed/Refractory FLT3+ AML. <i>Blood</i> , 2016, 128, 2744-2744.	1.4	17
146	Myelodysplastic Syndromes with NPM1 Mutations May Constitute a Unique Entity Associated with Improved Outcomes When Treated with AML-like Chemotherapy. <i>Blood</i> , 2016, 128, 3171-3171.	1.4	2
147	CPX-351 for the Treatment of High-Risk Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 4047-4047.	1.4	7
148	Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML. <i>Journal of Clinical Oncology</i> , 2016, 34, 7008-7008.	1.6	71
149	Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2015, 90, 276-281.	4.1	139
150	MDM2 Inhibitor, Nutlin 3a, Induces p53 Dependent Autophagy in Acute Leukemia by AMP Kinase Activation. <i>PLoS ONE</i> , 2015, 10, e0139254.	2.5	23
151	Phase I Study of S-Trans, Trans-Farnesylthiosalicylic Acid (Salirasib), a Novel Oral RAS Inhibitor in Patients With Refractory Hematologic Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 433-438.e2.	0.4	27
152	Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. <i>Lancet Haematology</i> , 2015, 2, e186-e193.	4.6	227
153	Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. <i>Leukemia Research</i> , 2015, 39, 950-956.	0.8	69
154	Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials. <i>Lancet Haematology</i> , 2015, 2, e118-e128.	4.6	65
155	Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. <i>Cancer</i> , 2015, 121, 2375-2382.	4.1	40
156	REVEAL, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2015, 168, 796-805.	2.5	27
157	Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study. <i>Lancet Haematology</i> , 2015, 2, e376-e383.	4.6	86
158	Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. <i>Leukemia Research</i> , 2015, 39, 1367-1374.	0.8	48
159	The Peptidic CXCR4 Antagonist, BL-8040, Significantly Reduces Bone Marrow Immature Leukemia Progenitors By Inducing Differentiation, Apoptosis and Mobilization: Results of the Dose Escalation Clinical Trial in Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 2546-2546.	1.4	15
160	Efficacy and safety of an anti-FLT3 antibody (LY3012218) in patients with relapsed acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2015, 33, 7059-7059.	1.6	11
161	Tyrosine Kinase Inhibitors as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated Phase. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 155-162.e1.	0.4	51
162	HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. <i>Cancer</i> , 2014, 120, 373-380.	4.1	54

#	ARTICLE	IF	CITATIONS
163	Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG+GO) as frontline regimen in patients with core binding factor acute myelogenous leukemia. American Journal of Hematology, 2014, 89, 964-968.	4.1	62
164	Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3 tyrosine kinase domain mutations. Cancer, 2014, 120, 2142-2149.	4.1	107
165	Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia. Cancer Discovery, 2014, 4, 362-375.	9.4	561
166	A Phase 1b/2a Study of Birinapant in Combination with 5-Azacytidine in Patients with Myelodysplastic Syndrome Who Are Naïve, Refractory to or Have Relapsed on 5-Azacytidine: a Preliminary Analysis. Blood, 2014, 124, 3263-3263.	1.4	4
167	Results of a Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients (Pts) with Activating FLT3 Mutations. Blood, 2014, 124, 389-389.	1.4	86
168	Mobilization and elimination of FLT3-ITD+ acute myelogenous leukemia (AML) stem/progenitor cells by plerixafor, G-CSF, and sorafenib: Phase I trial results in relapsed/refractory AML patients.. Journal of Clinical Oncology, 2014, 32, 7033-7033.	1.6	11
169	Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≥60 years with newly diagnosed acute myeloid leukemia. American Journal of Hematology, 2013, 88, 961-966.	4.1	46
170	Lenalidomide as a novel treatment of acute myeloid leukemia. Expert Opinion on Investigational Drugs, 2013, 22, 389-397.	4.1	14
171	Therapy of Core Binding Factor Acute Myeloid Leukemia: Incremental Improvements Toward Better Long-Term Results. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 153-158.	0.4	13
172	Outcome After Failure of Second Generation Tyrosine Kinase Inhibitors Treatment As First-line Therapy for Patients With Chronic Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 477-484.	0.4	24
173	XIAP antisense therapy with AEG 35156 in acute myeloid leukemia. Expert Opinion on Investigational Drugs, 2013, 22, 663-670.	4.1	14
174	Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase Internal Tandem Duplication Status. Journal of Clinical Oncology, 2013, 31, 3681-3687.	1.6	321
175	Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood, 2013, 121, 4655-4662.	1.4	355
176	Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood, 2013, 121, 4867-4874.	1.4	124
177	Phase II Trial Of Cladribine and Low-Dose AraC (LDAC) Alternating With Decitabine In Older Patients With Acute Myeloid Leukemia (AML). Blood, 2013, 122, 5011-5011.	1.4	3
178	Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood, 2012, 120, 4840-4845.	1.4	193
179	Twice-Daily Fludarabine and Cytarabine Combination With or Without Gemtuzumab Ozogamicin is Effective in Patients With Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, and Blast- Phase Chronic Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2012, 12, 244-251.	0.4	34
180	Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer, 2012, 118, 4471-4477.	4.1	60

#	ARTICLE	IF	CITATIONS
181	Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia. <i>Cancer</i> , 2012, 118, 5819-5822.	4.1	17
182	Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. <i>Blood</i> , 2011, 117, 1822-1827.	1.4	64
183	Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia. <i>Cancer</i> , 2011, 117, 2145-2155.	4.1	91
184	Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement. <i>Cancer</i> , 2011, 117, 4869-4877.	4.1	50
185	Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. <i>Haematologica</i> , 2011, 96, 62-68.	3.5	185
186	Prediction of Early Death After Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia With Pretreatment Risk Scores: A Novel Paradigm for Treatment Assignment. <i>Journal of Clinical Oncology</i> , 2011, 29, 4417-4424.	1.6	287
187	Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase. <i>Journal of Clinical Oncology</i> , 2010, 28, 392-397.	1.6	231
188	Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 1856-1862.	1.6	347
189	Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 398-404.	1.6	227
190	Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2010, 51, 73-78.	1.3	38
191	Activation of p53 signaling by MI-63 induces apoptosis in acute myeloid leukemia cells. <i>Leukemia and Lymphoma</i> , 2010, 51, 911-919.	1.3	15
192	Phase I/II Trial of AEG35156 X-Linked Inhibitor of Apoptosis Protein Antisense Oligonucleotide Combined With Idarubicin and Cytarabine in Patients With Relapsed or Primary Refractory Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2009, 27, 4741-4746.	1.6	115
193	Clofarabine: emerging role in leukemias. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1559-1564.	4.1	8
194	Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia. <i>Cancer</i> , 2009, 115, 3217-3221.	4.1	76
195	Therapy of Acute Myelogenous Leukemia in Adults. <i>Cancer Treatment and Research</i> , 2009, 145, 257-271.	0.5	0
196	Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies. <i>Cancer</i> , 2008, 113, 360-366.	4.1	7
197	Treatment of core-binding factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival. <i>Cancer</i> , 2008, 113, 3181-3185.	4.1	68
198	Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. <i>Leukemia and Lymphoma</i> , 2008, 49, 690-695.	1.3	106

#	ARTICLE	IF	CITATIONS
199	A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. <i>Blood</i> , 2008, 112, 1638-1645.	1.4	199
200	Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. <i>Cancer</i> , 2007, 109, 1556-1560.	4.1	89
201	The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia.. <i>British Journal of Haematology</i> , 2007, 136, 624-627.	2.5	223
202	Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab ? incidence and predictors. <i>British Journal of Haematology</i> , 2007, 136, 800-805.	2.5	83
203	Therapy-related acute myelogenous leukemia and myelodysplastic syndrome. <i>Current Oncology Reports</i> , 2007, 9, 373-377.	4.0	45